ManagementSun Pharma, Forest settle US suit on Lexapro
Sun Pharmaceutical Industries and its subsidiary, Caraco Pharmaceutical Laboratories, have reached a settlement agreement with drugmaker Forest Laboratories and licensing partner H Lundbeck AS, over a pending patent infringement dispute over Forest’s blockbuster antidepressant, Lexapro.
- Sun Pharma gets USFDA nod for generic anti-cancer drug - Sun extends Taro open offer to April 17">Sun extends Taro open offer to April 17 - Sun Pharma announces US nod for Topamax tablets - Sun, Taro chiefs meet for out-of-court settlement
Caraco had filed an application with the US Food and Drug Administration (USFDA) to launch a cheaper version of Lexapro, but Forest and H Lundbeck AS moved to block the drug, alleging it infringed the company’s patents.
Under the agreement announced by the companies, Forest will give Caraco patents to Lexapro, when other generic versions of the drug become available. Caraco will also take over sales of certain Forest products.